Merck's Covid pill might cause dangerous mutations, in both the virus and human DNA

[gaze]

a nice double whammy

Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1)

As much as people are justifiably excited about the prospect for orally available drugs that can prevent and treat Covid-19, I believe the FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval.

www.forbes.com

Merck’s new “miracle” covid drug found to cause cancerous mutations in hamster experiments

New research out of the University of North Carolina (UNC) found that Merck’s new anti-covid drug molnupiravir causes cancer. The so-called “miracle” drug, which we reported is really just a rip-off of ivermectin, was applied to hamster cells over the course of 32 days. During this time, it was...

www.newstarget.com

 

[Jkbp]

The second article compares Merck’s new drug to ivermectin. Are there similar risks when taking ivermectin? I just finished a 9 day course of ivermectin, to treat covid.

 

[Perry Staltic]

The second article compares Merck’s new drug to ivermectin. Are there similar risks when taking ivermectin? I just finished a 9 day course of ivermectin, to treat covid.

None whatsoever

 

[gaze]

The second article compares Merck’s new drug to ivermectin. Are there similar risks when taking ivermectin? I just finished a 9 day course of ivermectin, to treat covid.

yea none. not sure why the article stated that, if anything the pfizer pill is more like ivermectin.

 

[Jkbp]

ok good to know!

 

[gaze]

another interesting thing to go note is the Mercks pill was being taken in Gauteng where its likely the new variant emerged from:

Omicron Origins

Here we detail three possible origins of the new variant of concern: Omicron.

www.forbes.com

"Molnupiravir-induced

The final theory, and perhaps the most troubling one, is that Omicron is a result of our own doing, through the treatment of a Covid-19 patient with the highly mutagenic antiviral drug molnupiravir. Molnupiravir works by introducing errors into the virus’ genetic code. When enough errors are introduced, virus replication slows and the patient clears the virus.

Under less than ideal conditions — when the full dose of molnupiravir is not taken over the full period of five days, for example — the drug could lead to the creation of highly mutated, but viable, strains of SARS-CoV-2. Even under ideal conditions, patients treated with molnupiravir produced viable virus a few days into their course of treatment. The extent of the mutations which appeared due to molnupiravir are significant. In the FDA analysis of Merck’s clinical trial results, the authors note that patients who received molnupiravir showed more viral variation than those who did not, including amino acid substitutions, deletions or insertions in the spike gene, and amino acid changes were scattered throughout the coding sequence. A total of 72 emergent spike substitutions or changes was detected among 38 molnupiravir-treated patients.

In South Africa, where Omicron was first detected, molnupiravir has been taken in both ideal and non-ideal conditions. Four different South African locations were used in Merck’s clinical trial of molnupiravir, which began in October 2020. The drug was given to patients at what we now know to be the “optimal” dosage, but also at lower doses to test the drug’s efficacy in smaller amounts. There is by no means a foolproof connection between molnupiravir and Omicron, but molnupiravir is known to induce a preponderance of two types of mutations: cytosine to uridine (C→U) and guanosine to adenosine (G→A). If you look at the difference in the Omicron genome and the original Wuhan variant, these C→U and G→A mutations comprise the majority of differences, with C→U mutations more prevalent to G→A. The same has been observed for molnupiravir-induced mutations in other coronaviruses (see Figure below). Agostini et al. note that exposure to molnupiravir resulted in up to 162 mutations in MHV and 41 mutations in MERS-CoV."

 

[minni]

See related video below. I bet the pills already have "compliance ensuring" biochips embedded inside.
Yep, despite Pfizer's Bourla stating that biochips requires funding. Why would I believe these guys?

Marcel D. : Albert Bourla, PDG de Pfizer, discute de la puce électronique

View Marcel D. : Albert Bourla, PDG de Pfizer, discute de la puce électronique on Odysee

odysee.com